HomeStructural heart diseaseValvular Aortic Valve

Valvular Aortic Valve

View Category
Antiplatelet

Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines

The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement...
solaci -
Learn More
Institutional News

29/04 | Webinar SOLACI – TAVI TALKS: Why Hemodynamics Really Matters

solaci -
Learn More
Structural heart disease

Cerebral Protection Devices during TAVR in the Daily Practice

The theory behind the use of cerebral protection devices during TAVR is good, but hard to test....
solaci -
Learn More
Structural heart disease

TAVR vs. the Least Invasive Surgically Implanted Valve

Rapid-deployment surgically implanted valves are designed to make a surgeons’ job faster and easier, compared with conventional...
solaci -
Learn More
Antithrombotic Anticoagulants

The Best Anticoagulant Agent for AF After TAVR

Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation (AF) discharged after...
solaci -
Learn More
Valvular Aortic Valve

Silent Stroke During TAVR and Early Cognitive Impairment

Silent stroke is common after transcatheter aortic valve replacement (TAVR). Co-morbidities such as diabetes or chronic renal...
solaci -
Learn More
Structural heart disease

SCOPE I: Acurate NEO vs Sapien 3, no non-inferiority at one year?

The randomized controlled study SCOPE 1 failed to show significant differences at one year between the self-expandable...
solaci -
Learn More
Structural heart disease

Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis

Recent randomized trials including low-risk patients showed positive results for transcatheter aortic valve replacement (TAVR) compared with...
solaci -
Learn More